MISSISSAUGA, ON, Nov. 4, 2024 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") today announced that it will release its financial results for the third quarter of 2024 after the market close on Thursday, November 7, 2024. The Company will also hold a conference call on Friday, November 8, 2024 at 8:30am ET to discuss the results and corporate developments.
CONFERENCE CALL DETAILS
DATE: | Friday, November 8, 2024 |
TIME: | 8:30 a.m. ET |
DIAL-IN NUMBER: | 416-945-7677 or 888-699-1199 |
REPLAY: | 289-819-1450 or 888-660-6345 Code: 02131# |
Expires: November 15, 2024 | |
WEBCAST: |
About Cipher Pharmaceuticals Inc.
Cipher Pharmaceuticals (TSX: CPH, OTCQX: CPHRF) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products, mainly in dermatology. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and currently markets those products in Canada, the U.S., and South America. For more information, visit www.cipherpharma.com.
| Last Trade: | C$13.08 |
| Daily Change: | -0.25 -1.88 |
| Daily Volume: | 35,237 |
| Market Cap: | C$335.110M |
May 08, 2025 April 29, 2025 November 07, 2024 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
